A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations

This phase I trial was conducted to determine the maximum tolerated dose (MTD) and recommended dose of afatinib for phase II trial in elderly patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The study used a standard 3 + 3 dose es...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Med Oncol
Päätekijät: Tanaka, Hisashi, Taima, Kageaki, Tanaka, Yoshihito, Itoga, Masamichi, Ishioka, Yoshiko, Nakagawa, Hideyuki, Baba, Keisuke, Hasegawa, Yukihiro, Takanashi, Shingo, Tasaka, Sadatomo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2018
Aiheet:
Original Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5805799/
https://ncbi.nlm.nih.gov/pubmed/29423683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-018-1098-3
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia